Systemischer Lupus erythematodes

详细信息    查看全文

• 作者：Prof. Dr. M. Aringer (1)
  F. Hiepe (2)
  
• 关键词：Systemischer Lupus erythematodes ; Nephritis ; Autoantik枚rper ; Organbeteiligung ; Therapie ; Lupus erythematosus ; systemic ; Nephritis ; Autoantibodies ; Organ involvement ; Therapy
• 刊名：Zeitschrift f篓鹿r Rheumatologie
• 出版年：2011
• 出版时间：June 2011
• 年：2011
• 卷：70
• 期：4
• 页码：313-323
• 全文大小：503KB
• 参考文献：1. Alexander T, Thiel A, Rosen O et al (2009) Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 113:214鈥?23 f="http://dx.doi.org/10.1182/blood-2008-07-168286">CrossRef
  2. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725 f="http://dx.doi.org/10.1002/art.1780400928">CrossRef
  3. Bertsias G, Ioannidis JP, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67:195鈥?05 f="http://dx.doi.org/10.1136/ard.2007.070367">CrossRef
  4. Petri M, Kim MY, Kalunian KC et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353:2550鈥?558 f="http://dx.doi.org/10.1056/NEJMoa051135">CrossRef
  5. Mosca M, Tani C, Aringer M et al (2010) European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 69:1269鈥?274 f="http://dx.doi.org/10.1136/ard.2009.117200">CrossRef
  6. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69:20鈥?8 f="http://dx.doi.org/10.1136/ard.2008.101766">CrossRef
  7. Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295鈥?06 f="http://dx.doi.org/10.1111/j.1538-7836.2006.01753.x">CrossRef
  8. Bertsias GK, Ioannidis JP, Aringer M et al (2010) EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69:2074鈥?082 f="http://dx.doi.org/10.1136/ard.2010.130476">CrossRef
  9. Weening JJ, D鈥橝gati VD, Schwartz MM et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521鈥?30 f="http://dx.doi.org/10.1111/j.1523-1755.2004.00443.x">CrossRef
  10. Houssiau FA, Vasconcelos C, D鈥機ruz D et al (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69:61鈥?4 f="http://dx.doi.org/10.1136/ard.2008.102533">CrossRef
  11. Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103鈥?112 f="http://dx.doi.org/10.1681/ASN.2008101028">CrossRef
  12. Winzer M, Aringer M (2010) Use of methotrexate in patients with systemic lupus erythematosus and primary Sjogren鈥檚 syndrome. Clin Exp Rheumatol 28(5 Suppl 61):S156鈥揝159
  13. Galie N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493鈥?537 f="http://dx.doi.org/10.1093/eurheartj/ehp297">CrossRef
  14. Kuhn A, Ochsendorf F, Bonsmann G (2010) Treatment of cutaneous lupus erythematosus. Lupus 19:1125鈥?136 f="http://dx.doi.org/10.1177/0961203310370345">CrossRef
  15. Navarra SV, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721鈥?31 f="http://dx.doi.org/10.1016/S0140-6736(10)61354-2">CrossRef
  16. Jonsdottir T, Gunnarsson I, Mourao AF et al (2010) Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford) 49:1502鈥?504
  17. Stummvoll GH, Julius U, Derfler K, Aringer M (2009) Immunoadsorption for systemic lupus erythematosus. Atheroscler Suppl 10:110鈥?13 f="http://dx.doi.org/10.1016/S1567-5688(09)71823-9">CrossRef
  
• 作者单位：Prof. Dr. M. Aringer (1)
  F. Hiepe (2)
  
  1. Medizinische Klinik und Poliklinik III, Universit盲tsklinikum Carl Gustav Carus an der Technischen Universit盲t Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland
  2. Med. Klinik m. S. Rheumatologie u. Klin. Immunologie, Charit茅 - Universit盲tsmedizin Berlin, Berlin, Deutschland
  

文摘

Systemic lupus erythematosus (SLE) is the classical systemic autoimmune disease. Its prevalence is slightly below 1:1,000 in women and 10-fold lower in men. Typically, the disease manifests in women of childbearing age. While severe untreated SLE used to be a fatal disease, prognosis has improved stepwise with corticosteroids, cyclophosphamide and novel therapies. Deaths directly related to SLE are uncommon nowadays but infections, thromboses and accelerated atherosclerosis cause significant problems. The current review presents the state of the art in managing SLE patients.